Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02626234
Title A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Capmatinib

Age Groups: adult
Covered Countries USA | ITA | ESP | BEL | AUT

Facility Status City State Zip Country Details
Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group Atlanta Georgia 30322 United States Details
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756 United States Details
Novartis Investigative Site Vienna A-1090 Austria Details
Novartis Investigative Site Edegem Antwerpen 2650 Belgium Details
Novartis Investigative Site Brno 65653 Czechia Details
Novartis Investigative Site Ioannina GR 455 00 Greece Details
Novartis Investigative Site Athens 18547 Greece Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Candiolo TO 10060 Italy Details
Novartis Investigative Site Bologna 40138 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Madrid 28222 Spain Details
Novartis Investigative Site London W1G 6AD United Kingdom Details
Novartis Investigative Site Manchester M20 9BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field